Skip to main content
. Author manuscript; available in PMC: 2015 Jun 15.
Published in final edited form as: Clin Cancer Res. 2014 Apr 11;20(12):3289–3298. doi: 10.1158/1078-0432.CCR-13-3360

Figure 2.

Figure 2

The Primary Endpoint, Ki-67 Proliferation Index. (A) The primary omnibus hypothesis demonstrated a significant difference in Ki-67 modulation among groups (two-sided Kruskal-Wallis, p=0.04). Depicted in this box and whisker plot are the Wilcoxon pairwise contrasts confirming a significant decrease in Ki-67 for patients treated with either erlotinib or erlotinib-sulindac vs. placebo. Box and whisker plots consist of the median (white line), the inter-quartile range (box) and the distance to observed values within 1.5 times the inter-quartile range (whiskers). (B) A waterfall plot depicts the intra- patient change in tumoral Ki-67 expression, pre and post-treatment. Bars are color-coded according to treatment arm.